pepstash

  • How Tesamorelin Works — and What Animal Studies Tell Us

    ·

    pepstash

    Tesamorelin (a GHRH analog) activates pituitary GHRH receptors, boosting pulsatile GH and hepatic IGF-1 to drive lipolysis and anti-lipogenic effects. Foundational animal studies in rats and dogs—supported by FDA reviews—show dose-responsive GH/IGF-1 rises and class-consistent, reversible findings at higher exposures, with negative genotoxicity and no impairment of rat fertility at clinically comparable exposure.

    Read More

  • BPC-157: Between Regeneration Hype and Human Evidence

    ·

    pepstash

    BPC-157, a gastric-derived peptide hailed for regenerative effects in animals, is gaining global attention despite minimal human evidence. This research briefing separates verified science from speculation — reviewing animal data, routes of administration, pharmacokinetics, regulatory status, and the social forces fueling its rise. No approved human uses. For research only.

    Read More

  • Regulatory Tightening: FDA Bulk Substance Policy Redefines Peptide Compounding

    ·

    pepstash

    Why it matters The U.S. FDA is moving from a period of discretionary enforcement to active restriction of unlisted bulk drug substances used in compounding. This shift directly impacts how pharmacies, clinics, and research suppliers can handle many well-known peptides—including BPC-157, TB-500, and Epitalon—used historically under gray-zone exemptions. Study snapshot / Policy background Key findings…

    Read More